
Carlsmed Inc (CARL) Stock Forecast & Price Target
Carlsmed Inc (CARL) Analyst Ratings
Bulls say
Carlsmed is a promising investment opportunity due to its potential for strong revenue growth and impressive gross margins in the near term. With a growing customer base and the recent success of its FDA-cleared aprevo technology, there is potential for further expansion into the cervical spine market. With strong reimbursement rates and a vertically-integrated manufacturing process, Carlsmed is positioned for success in the spine surgery market. However, potential risks include a concentrated customer base and the need for additional capital to reach profitability.
Bears say
Carlsmed is currently trading at a low multiple of 4.0x compared to its peers, despite a top-line CAGR of 43%. However, our negative outlook stems from concerns over inconsistent utilization rates among existing surgeons and the lower-than-expected sales forecast for aprevo in cervical procedures. Additionally, operating expenses are expected to remain high, which could hinder the company's profitability in the near future.
This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.
Carlsmed Inc (CARL) Analyst Forecast & Price Prediction
Start investing in Carlsmed Inc (CARL)
Order type
Buy in
Order amount
Est. shares
0 shares